Global Anti-Parkinsons Drugs Market Witnessed to Surge at a CAGR of 6.1% by the End of 2022

Published on : Mar 19, 2018

Albany, New York, March 19, 2018: A comprehensive study on anti-parkinsons drugs has been recently added to the wide database of Market Research Hub (MRH), with the title of “Anti-Parkinsons Drugs: Global Markets to 2022”. This research aims to provide useful information to the investors of the report by highlighting anti-parkinsons drugs market-related data throughout the forecast period of 2017-2022 in terms of revenue (in US$ Bn). Moreover, the report also highlights opportunities in this particular market at the global and regional level. Prime regions emphasized in the study are North America, Western Europe, Asia Pacific, Middle East & Africa (MEA).

An overview of the global market for anti-Parkinson’s drugs and their future demand has been presented in the initial section, covering overall information of various segments and sub-segments considered in the scope of the study. In addition to detailed segmentation, the report also offers qualitative and quantitative analysis on the market. Analysis of the key drivers, restraints, opportunities, and threats has been offered lucidly for the perusal of readers. 

Prime Highlights of the Study

Parkinson's disease is a progressive disorder of the nervous system. A person with Parkinson's disease slowly loses the ability to control body movements. It has been analyzed that treatment of disease usually consists of drug therapy, physical therapy and the use of devices that permit patients to lead productive lives. Drug treatment is the main method used to control the symptoms of Parkinson's. In this study, discussion of the major segments of the anti-Parkinson’s drugs, i.e., dopaminergic drugs, dopamine agonists, enzyme inhibitors and other anti-Parkinson’s medications has been given.

At present, there is intensifying pressure to enhance research technologies, improving quality of the drugs and satisfy patients, as it is a serious disease widespread in all countries. This is contributing towards market growth positively. As per the research key findings, the global anti-Parkinson’s drugs market should reach $5.7 billion by 2022 from $4.2 billion in 2017 at an impressive CAGR of 6.1% from 2017 to 2022.

Moreover, the research also finds that emerging market growth, swelling awareness, rapid urbanization, rising aging population, improving technology and growth in the pharmaceutical industry is driving the demand for anti-Parkinsons drugs. In terms of geography, North America is the largest market for anti- Parkinsons drugs manufacturing, which is also estimated to remain same during the mentioned forecast.

Country-wise analysis segment reveals that the USA is the largest market in terms of value and in the anti-Parkinsons drugs market. On the other hand, China and Brazil are forecasted to have the fastest growth in the future.

A vital section of the report is competitive landscape which highlights details about major market leaders. Major players functioning in the market are Novartis, AbbVie, GlaxoSmithKline, Zambon Pharmaceuticals and others.

Request a Sample with TOC in a PDF format :

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email :

Back To Top